Navigation Links
Pharmaceutical in Medical Technology

European Division of Global Top 20 Pharmaceutical Company Awards Phase III Trial to DATATRAK

CLEVELAND, July 28 /PRNewswire-FirstCall/ -- DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced that a European Division within a Global Top 20 Pharmaceutical organization has selected DA...

Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction

Management will host Conference Call at 9:00 AM ET Today CORAL GABLES, Fla., May 29 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) today announced top-line results from its U.S. Phase II clinical trial to treat cocaine addiction. The data from the trial ...

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)

TITUSVILLE, N.J., Feb. 6 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) today announced that the company has submitted multiple applications to the U.S. Food and Drug Administration (FDA) which, if approved, would broaden treatment options for...

Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study

NANJING, China, Sept. 3 /PRNewswire-FirstCall/ -- Simcere Pharmaceutical Group (NYSE: SCR ), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu (also known as Endostar) in China, announced the interim result...

Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss

CORAL GABLES, Fla., Aug 21 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) today reported that animal data from a new study sponsored by scientists at the U.S. Department of Energy's Brookhaven National Laboratory appears to demonstrate that taking vigabatrin ...

Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction

CORAL GABLES, Fla., June 30 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX ), a biopharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction and obsessive compulsive disorders, today ...

Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting

LA JOLLA, Calif., June 2 /PRNewswire-FirstCall/ -- Alliance Pharmaceutical Corp. (OTC Bulletin Board: ALLP) announced today the results of the vote of its shareholders on the two proposals put to the shareholders at its Annual Meeting of Shareholders held Friday, May 30, 2008. The first prop...

TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis

-- Additional Data Demonstrated Higher Overall Maintenance of Healed Erosive Esophagitis and Symptom Relief versus Placebo -- SAN DIEGO, May 18 /PRNewswire/ -- TAP Pharmaceutical Products Inc. today reported results from three pivotal Phase 3 studies evaluating investigational new dru...

Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today that Taisho Pharmaceutical Co., Ltd. initiated a Phase 1 clinical trial of a drug candidate under a GPCR-focused partnership with Arena to develop compounds to treat psychiatric disorders. T...

Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results

-- Currently enrolling patients in U.S. Phase II clinical trial for cocaine addiction -- Expect to initiate U.S. Phase II clinical trial for methamphetamine addiction in second quarter of 2008 CORAL GABLES, Fla., March 26 /PRNewswire-FirstCall/ -...

BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)

- Data provides evidence of survival increase in advanced non-small cell lung cancer patients receiving Tavocept in conjunction with paclitaxel and cisplatin - Multiple statistically significant findings include reductions in chemotherapy-induced kidney...

Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies

OMAHA, Neb., March 5 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO), a leading global genetic analysis company, today announced that it has entered into agreements with two major Pharmaceutical companies for three Phase II trials representing more than $500,000 in the ...

Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction

- Additional Clinical Trial Sites To Be Added - - Fast Track Status With FDA - CORAL GABLES, Fla., Jan. 25 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX ), a biopharmaceutical company that acquires, in-licenses, develops and com...

Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan

SAN DIEGO, Nov. 21 /PRNewswire-FirstCall/ -- Alliance Pharmaceutical Corp. (OTC Bulletin Board: ALLP). Following a Steering Committee meeting last week in China with its partner Beijing Double-Crane Pharmaceutical Co., Ltd. (Double-Crane), Alliance has updated its clinical development plan for...

Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development

- Pfizer-funded Screening Agreement Fuels Discovery of Novel Compounds, Complements Clinical Development Initiatives with PF-3512676 - WELLESLEY, Mass., Oct. 30 /PRNewswire-FirstCall/ -- Coley Pharmaceutical Group, Inc. (Nasdaq: COLY ), a biopharmaceutical company discovering and developi...

Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus

-- CPG 52364, Coley's First Orally-Available, Small Molecule Drug Candidate, Enters Phase I Clinical Development -- WELLESLEY, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Coley Pharmaceutical Group, Inc. (Nasdaq: COLY ), today announced that it has dosed its first subject in a Phase...

Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline

WELLESLEY, Mass., Oct. 26 /PRNewswire-FirstCall/ -- Coley Pharmaceutical Group, Inc. (Nasdaq: COLY ), today announced that the company has received a $3.0 million milestone payment from GlaxoSmithKline (GSK) associated with the initiation of GSK's Phase III clinical trial in non-small cell lu...

The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy

DOYLESTOWN, Penn., Oct. 25 /PRNewswire-FirstCall/ -- The Quigley Corporation (Nasdaq: QGLY ) today reported net sales of $11.8 million, for the third quarter ended September 30, 2007, compared to $11.5 million reported for the same period in 2006. For the nine-months ended September 30, 2007,...

CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase

VIENNA, Va., Oct. 18 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM ) announced today that its Chief Executive Officer, Geert Kersten, is a featured presenter at the International Society for Pharmaceutical Engineering (ISPE) 2007 Chesapeake BioShowcase in Gaithersburg Maryland. Mr....

West Pharmaceutical Services, Inc. Appoints New Director

LIONVILLE, Pa., Oct. 16 /PRNewswire-FirstCall/ -- West Pharmaceutical Services, Inc. (NYSE: WST ) today announced the appointment to its Board of Directors of Mr. Thomas W. Hofmann. Mr. Hofmann, 56, is Senior Vice President and Chief Financial Officer of Sunoco, Inc. (NYSE: SUN ), a position...

Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity

BOTHELL, Wash., Oct. 1 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK ) announced today the start of a Phase 2 clinical trial evaluating the Company's PYY3-36 Nasal Spray in obese patients. The study will enroll approximately 500 obese patients for a six-month, ra...

Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes

- Rapid-Acting, Non-Invasive Nasal Spray Dosage form is Patient Friendly and Avoids Potential Safety Concerns of Pulmonary Delivery - BOTHELL, Wash., Sept. 26 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK ) announced today the start of a Phase 2 clinical tri...

Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations

ASHBURN, Va., Sept. 26 /PRNewswire/ -- Innocoll, Inc., a privately-held specialty pharmaceutical company, announced the following status and progress updates regarding its clinical development programs and specialty pharmaceutical operations: - Three Investigational New Drug (IND) Application...

Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)

WOODCLIFF LAKE, N.J., Aug. 3 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX ) today announced it had begun shipping metoprolol succinate extended release 50 mg tablets. As previously announced, in November 2006 Par entered into a supply and distribution agreement with...

Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline

Research by CMR Shows Revenue Derived from New Products Launched within the Last Five Years has Dropped to Just 16% of Total Revenue in 2006 PHILADELPHIA, Aug. 15 /PRNewswire-FirstCall/ -- Thomson Scientific, part of The Thomson Corporation (NYSE: TOC ; TSX: TOC) and leading provider of info...

La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent Lupus Phase 3 Trial

Data Support Ability of Higher Doses to Further Reduce Antibodies to Double-Stranded DNA SAN DIEGO, March 08, 2007 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company today announced positive interim antibody results from its ongoing double-blind, placebo-controlled randomized Phase 3 trial ...

La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent Lupus Phase 3 Trial

SAN DIEGO, March 20, 2007 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company today announced updated interim antibody reduction data for the Phase 3 trial of Riquent(R) (abetimus sodium), its drug candidate for systemic lupus erythematosus ("lupus" or "SLE"). The updated analyses reinforce ...

Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Company's Investigational Drug to Treat Cocaine and Methamphetamine Addiction

CORAL GABLES, Fla., May 09, 2007 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. announced today positive initial, top-line results from a bioequivalence study demonstrating that CPP-109 (Catalyst's Vigabatrin Tablets) is bioavailable and bioequivalent to Sabril Tablets, the versi...

DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp

CUPERTINO, Calif., May 17, 2007 /PRNewswire-FirstCall/ -- DURECT Corporation announced today that Voyager Pharmaceutical has provided its shareholders with an update on its truncated Phase 3 clinical trial for Memryte, an investigational drug for the treatment of Alzheimer's disease. Voyager has i...

Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 4, 2007 - Researchers at Molecular Insight Pharmaceuticals today announced the presentation of preclinical data on MIP-1072, a radiolabeled, small molecule molecular imaging pharmaceutical in development for diagnosis and staging of prostate cancer at the 54th...

Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company

Statement by Sandra C. Raymond, President & CEO of the Lupus Foundation of America, Inc. WASHINGTON, June 27, 2007 /PRNewswire-USNewswire/ -- The Lupus Foundation of America, Inc. and more than 1.5 million Americans with lupus have been awaiting the preliminary findings of the Phase III clinic...

Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA

...H1N1) 2009 vaccine clinical trials is available at www.clinicaltrials.gov . About sanofi-aventis Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN)...

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

...uideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our product...

SIRO Clinpharm Completes Successful Implementation of Oracle Life Sciences Application Suite

...y and medical devices sectors in compliance with international standards. SIRO is one of the first CROs founded in India, which caters to the needs of pharmaceutical companies across the world. The company has offices in India, USA, Israel and in Germany, Romania, Estonia and Greece. SIRO has recently opened office...

NewCardio Announces Master Services Agreement With Dedicated Phase I

... product is QTinno(TM), a software suite that provides an automated, comprehensive analysis of QT intervals and other ECG-based cardiac safety for the pharmaceutical industry and drug regulators. The Company believes that its QTinno(TM), software-based, analytical technology is the industry's first solution for the...

Labopharm files New Drug Submission with Health Canada for novel antidepressant

... pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www.labopharm.com . Thi...

Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930

... drug candidates. It develops its products for global registration and maximum commercial potential. Once registered, the products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide development of all of its products while providing expertise in ...

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

...guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our product...

Project Zero Delay Accelerates Drug's Path to Clinical Trial

...Investigators from The University of Texas M. D. Anderson Cancer Center and pharmaceutical company AstraZeneca have reported their work in the Journal of Clinical O...supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gast...

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

...tic Area Head, Neuroscience, Johnson & Johnson pharmaceutical Research & Development. "The approval of INVEG...STENNA(TM) was developed by Johnson & Johnson pharmaceutical Research & Development, L.L.C. (J&JPRD), a...s based in Titusville, N.J., and is the only large pharmaceutical company in the U.S. dedicated solely to mental hea...
Other Tags
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation ... is this more evident than at international borders. ... secure document scanners have allowed veteran travelers to ... Automated Passport Control (APC) Kiosks at an increasing ... the globe. According to ...
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist ... education building for its School of Medicine. Funding for ... larger capital campaign that will be publicly launched next ... be located in the former 60 series R.J. Reynolds ... Innovation Quarter. Construction will begin immediately with plans to ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
(Date:12/26/2014)... December 26, 2014 It is said that ... dress. Today, UWDress.com, the famous wedding dress supplier, shows ... a site-wide cocktail gown promotion. , UWDress.com’s navy cocktail ... and they come in high fashion styles. Simple dresses in ... on the occasion; they are specially designed for those who ...
(Date:12/26/2014)... December 26, 2014 Yisrayl Hawkins, Pastor at ... open letter in light of the Ferguson, Missouri unrest. Yisrayl ... civil unrest and explains why it has only increased. ... was even created. He says there is a very specific ... also says there is a set of rules, or Laws ...
(Date:12/26/2014)... 26, 2014 Plugin and template developers from ... 5 Plugin for Final Cut Pro X. , “TransPack Volume ... tool to pull off an industry professional look” Said Christina ... hands on TransPack Volume 5, a new level of professionalism ... set of over 50 Final Cut Pro X transitions featuring ...
(Date:12/26/2014)... India Network Foundation, a non-profit US based ... today a new version of “ EasySelect ”, a ... plan for their visiting parents. The technology tool is ... process when choosing an insurance plan by showing the ... few clicks. Many elderly Asian Indian parents often find ...
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a comprehensive high-tech ... marketing of a series of induction heating equipment. Today, ... of induction brazing equipments . , According to ... refers to the joining of two or more ... manager says that there are fundamental differences in the ...
Breaking Medicine News(10 mins):Health News:UWDress.com Shows Its New Navy Cocktail Dresses For 2015 2Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2
Other Contents